Skip to main content
. 2023 Feb 1;15(3):933. doi: 10.3390/cancers15030933

Figure 2.

Figure 2

Effects of PD-1 expression and blocking on ILC2s. IL-33-activated ILC2s up-regulate PD-1 in order to limit proliferation and cytokine secretion (A). In the melanoma TME, PD-1 blocking by monoclonal antibodies counteracts such restraint, allowing ILC2s to proliferate and produce the cytokines promoting eosinophils infiltration (B).